

Pan tumor Roll Over Study

Estado
Reclutando

Tipo de Participantes
No aportado

Rangos de Edad
Mayores de 64 , Adultos (18-64 años)

Género
Ambos

Fases
Fase II

Participantes esperados
281

Resultados
Sin resultados

Bajo nivel intervención
No

Enfermedad rara
No

Cobertura geográfica
Sin determinar

Ámbitos del ensayo
seguridad

Terapia avanzada
NO

Información

Identificador
2023-506914-32-00 (CTIS)

Cod. Protocolo
CA209-8TT

Transicionado 2018-004362-34

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
Pan tumor

Título Científico
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Justificación

No aportado

Objetivo Principal

The main objective of this study is to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.

Variables de Evaluación Primaria

Incidence of adverse events (including related AEs, AEs leading to discontinuation, SAEs, select AEs, immune-mediated AEs, and deaths).

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

To follow participants who have completed therapy and are in or have completed follow-up on a Parent Study investigating nivolumab or nivolumab combination therapy for long-term efficacy (including overall survival [OS])
Safety of cancer therapies used as comparator in Parent Studies

Variables de Evaluación Secundaria

OS defined as date of randomization, first dose, or as defined in the Parent Study until date of death from any cause or censored on the last known alive date in the rollover study
Incidence of AEs.

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Signed Written Informed Consent
Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
Participant is eligible to receive continued study treatment per the Parent Study, including treatment beyond

progression per investigator assessment in the Parent Study.
Participant is on treatment hold in the Parent Study following longlasting response or are eligible for treatment rechallenge as defined in the Parent Study.

Criterios de Exclusión

For Participants planning to enter the study on nivolumab treatment: Participant is not eligible for study treatment per the Parent Study eligibility criteria

Participants with any condition which, in the judgment of the Investigator, may pose a significant risk to the participant.

In the case of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptoms must have completely resolved and based on investigator assessment, there are no sequelae that would place the participant at a higher risk of receiving investigational treatment.

Participants currently in other interventional trials, including those for coronavirus disease 2019 (COVID-19), may not participate in BMS clinical trials until the protocol-specific washout period is achieved. If a study participant has received an investigational COVID-19 vaccine or other investigational product designed to treat or prevent COVID-19 prior to screening, enrollment must be delayed until the biologic impact of the vaccine or investigational product is stabilized, as determined by the investigator

Participants not receiving clinical benefit as assessed by the Investigator

Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant

History of allergy or hypersensitivity to study drug components

Prisoners or participants who are involuntarily incarcerated (Note: Under certain specific circumstances and only in countries where local regulations permit, a person who has been imprisoned may be included or permitted to continue as a participant. Strict conditions apply and BMS approval is required

Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness

Dementia or serious psychiatric condition that may compromise the informed consent process and increase the risks associated with study participation

Calendario

(Última actualización: 24/06/2026)

Autorización 31/01/2020	Inicio de Ensayo 07/07/2020	Inclusión Primer Paciente 07/07/2020	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado

Promotor

Bristol-Myers Squibb Services Unlimited Company Ireland

Plaza 254Blanchardstown Corporate Park 2

Contact Person

GSM-CT

003223527611

mg-gsm-ct@bms.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Centros

Cerrado (24/05/2024)	CENTRO ONCOLÓGICO MD ANDERSON INTERNATIONAL ESPAÑA Madrid MADRID Oncology Department
No iniciado (--/--/----)	Clinica Universidad De Navarra Pamplona NAVARRA MEDICAL IMMUNOLOGY AND IMMUNOTHERAPY
No iniciado (--/--/----)	Clinica Universidad De Navarra Madrid MADRID MEDICAL IMMUNOLOGY AND IMMUNOTHERAPY
Cerrado (18/09/2024)	COMPLEXO HOSPITALARIO UNIVERSITARIO A CORUÑA Coruña, A CORUÑA
Activo (05/11/2020)	CONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA Valencia VALENCIA Oncology Department
Cerrado (15/05/2024)	FUNDACIÓN ONKOLOGIKOA FUNDAZIOA Donostia/San Sebastián GUIPÚZCOA Oncology Department
Cerrado (10/09/2024)	HOSPITAL CLÍNIC DE BARCELONA Barcelona BARCELONA Oncology Department
Activo (05/04/2024)	Hospital Clinic De Barcelona Barcelona BARCELONA Oncology

No iniciado (---/---/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Oncology

Cerrado (15/09/2022)

HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE

Alicante/Alacant

ALICANTE

Activo (25/11/2020)

Hospital General Universitario De Valencia

Valencia

VALENCIA

Oncology

Cerrado (20/09/2024)

HOSPITAL RAMÓN Y CAJAL

Madrid

MADRID

Oncology Department

Activo (02/10/2020)

HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA

Badalona

BARCELONA

No iniciado (---/---/----)

Hospital Universitari Vall D Hebron

Barcelona

BARCELONA

Oncology

Activo (22/01/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Cerrado (21/04/2022)

HOSPITAL UNIVERSITARIO DE BURGOS

Burgos

BURGOS

Activo (21/09/2020)

HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ

Madrid

MADRID

No iniciado (---/---/----)

Hospital Universitario Fundacion Jimenez Diaz

Madrid

MADRID

Oncology

No iniciado (---/---/----)

Hospital Universitario Hm Sanchinarro

Madrid

MADRID

Oncology

Cerrado (19/12/2025)

Hospital Universitario La Paz

Madrid

MADRID

Oncology

Activo (25/06/2020)

HOSPITAL UNIVERSITARIO MADRID SANCHINARRO

Madrid

MADRID

No iniciado (---/---/----)

Hospital Universitario Marques De Valdecilla

Santander

CANTABRIA

Oncology

Cerrado (31/07/2025)

HOSPITAL UNIVERSITARIO REGIONAL DE MÁLAGA

Málaga

MÁLAGA

Cerrado (31/07/2025)

Hospital Universitario Regional De Malaga

Malaga

MÁLAGA

Oncology

Cerrado (19/07/2024)

HOSPITAL UNIVERSITARIO VIRGEN
DEL ROCIO

Sevilla

SEVILLA

Oncología

Cerrado (10/07/2024)

HOSPITAL UNIVERSITARIO VIRGEN
MACARENA

Sevilla

SEVILLA

Activo (11/11/2021)

HOSPITAL UNIVERSITARIO Y
POLITÉCNICO LA FE

Valencia

VALENCIA

Activo (10/11/2020)

HOSPITAL UNIVERSITARIO 12 DE
OCTUBRE

Madrid

MADRID

No iniciado (---/---/---)

Hospital Universitario 12 De Octubre

Madrid

MADRID

Oncology

No iniciado (---/---/---)

Institut Catala D'oncologia

Badalona

BARCELONA

oncology

Cerrado (14/05/2025)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Medicamentos

PEMBROLIZUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

-

Principios Activos: N/A

Experimental

Mekinist 0.5 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01EE01 - TRAMETINIB

Principios Activos: N/A

Experimental

Sodiofolin 50 mg/ml, solution for injection/infusion

SOLUTION FOR INJECTION/INFUSION
INTRAVENOUS USE

Código ATC: V03AF06 - FOLINATO DE SODIO

Principios Activos: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET
ORAL USE

-

Principios Activos: N/A

Experimental

SUNITINIB

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

Temozolomide SUN 20 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

SUNITINIB

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

Sutent 37.5 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01EX01 - SUNITINIB
Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01BC06 - CAPECITABINA
Principios Activos: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

Principios Activos: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

Principios Activos: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

Principios Activos: N/A

Experimental

Relatlimab

SOLUTION FOR INFUSION
UNKNOWN USE

Principios Activos: N/A

Experimental

Avastin 25 mg/ml concentrate for solution for infusion.

SOLUTION FOR INFUSION
INTRAVENOUS USE

Mekinist 2 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01FG01 - BEVACIZUMAB

Principios Activos: N/A

Experimental

Código ATC: L01EE01 - TRAMETINIB

Principios Activos: N/A

Experimental

Temozolomide SUN 250 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Temozolomide SUN 20 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Temozolomide SUN 140 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Sutent 12.5 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

OXALIPLATIN

CONCENTRATE FOR SOLUTION FOR INFUSION
INTRAVENOUS USE

-

Principios Activos: N/A

Experimental

PEMETREXED

POWDER FOR CONCENTRATE FOR SOLUTION FOR
INFUSION
INTRAVENOUS USE

-

Principios Activos: N/A

Experimental

OPDIVO 10 mg/mL concentrate for solution for infusion.

SOLUTION FOR INFUSION
UNKNOWN USE

Código ATC: L01FF01 - NIVOLUMAB

Principios Activos: N/A

Experimental

Mekinist 0.5 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01EE01 - TRAMETINIB

Principios Activos: N/A

Experimental

TRAMETINIB

FILM-COATED TABLET
ORAL USE

-

Principios Activos: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

Temozolomide SUN 100 mg hard capsules

CAPSULE, HARD
ORAL USE

FLUOROURACIL

SOLUTION FOR INJECTION
INTRAVENOUS USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Principios Activos: N/A

Experimental

CABOMETYX 40 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01EX07 - CABOZANTINIB

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Sutent 25 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

Rubraca 200 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01XK03 - RUCAPARIB

Principios Activos: N/A

Experimental

BEVACIZUMAB

SOLUTION FOR INFUSION

INTRAVENOUS USE

Principios Activos: N/A

Experimental

OPDIVO 10 mg/mL concentrate for solution for infusion.

SOLUTION FOR INFUSION

UNKNOWN USE

Código ATC: L01FF01 - NIVOLUMAB

Principios Activos: N/A

Experimental

DARZALEX 20 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

KEYTRUDA 25 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

Código ATC: L01FC01 - DARATUMUMAB

Principios Activos: N/A

Experimental

Código ATC: L01FF02 - PEMBROLIZUMAB

Principios Activos: N/A

Experimental

CABOZANTINIB

FILM-COATED TABLET

ORAL USE

-

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Sutent 37.5 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET

ORAL USE

-

Principios Activos: N/A

Experimental

Avastin 25 mg/ml concentrate for solution for infusion.

SOLUTION FOR INFUSION

INTRAVENOUS USE

ALIMTA 500 mg powder for concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

Código ATC: L01FG01 - BEVACIZUMAB

Principios Activos: N/A

Experimental

Código ATC: L01BA04 - PEMETREXED

Principios Activos: N/A

Experimental

Mekinist 2 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01EE01 - TRAMETINIB

Principios Activos: N/A

Experimental

DARZALEX 20 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

Código ATC: L01FC01 - DARATUMUMAB

Principios Activos: N/A

Experimental

Stivarga 40 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01XE21 - REGORAFENIB

Principios Activos: N/A

Experimental

Temozolomide SUN 100 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Temozolomide SUN 180 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Oxaliplatin 5 mg/ml concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Código ATC: L01XA03 - OXALIPLATINO

Principios Activos: N/A

Experimental

Sutent 50 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

Sutent 25 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

Rubraca 250 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01XK03 - RUCAPARIB

Principios Activos: N/A

Experimental

Relatlimab

SOLUTION FOR INJECTION
SOLUTION FOR INFUSION

Principios Activos: N/A

Experimental

BEVACIZUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

Principios Activos: N/A

Experimental

DARATUMUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

Principios Activos: N/A

Experimental

Stivarga 40 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Temozolomide SUN 250 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01XE21 - REGORAFENIB

Principios Activos: N/A

Experimental

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

Temozolomide SUN 180 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

SUNITINIB

CAPSULE, HARD
ORAL USE

-

Principios Activos: N/A

Experimental

Sutent 12.5 mg hard capsules

CAPSULE, HARD
OTHER USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

YERVOY 5 mg/ml concentrate for solution for infusion

SOLUTION FOR INFUSION
UNKNOWN USE

TRAMETINIB

FILM-COATED TABLET
ORAL USE

Código ATC: L01FX04 - IPILIMUMAB

Principios Activos: N/A

Experimental

-

Principios Activos: N/A

Experimental

REGORAFENIB

FILM-COATED TABLET

ORAL USE

-

Principios Activos: N/A

Experimental

DISODIUM FOLINATE

SOLUTION FOR INJECTION/INFUSION

INTRAVENOUS USE

-

Principios Activos: N/A

Experimental

Temozolomide SUN 140 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD

ORAL USE

-

Principios Activos: N/A

Experimental

Xtandi 40 mg soft capsules

CAPSULE, SOFT

ORAL USE

Código ATC: L02BB04 - ENZALUTAMIDA

Principios Activos: N/A

Experimental

ENZALUTAMIDE

CAPSULE, SOFT

ORAL USE

-

Principios Activos: N/A

Experimental

CABOZANTINIB

FILM-COATED TABLET

ORAL USE

TEMOZOLOMIDE

CAPSULE, HARD

ORAL USE

–

Principios Activos: N/A

Experimental

–

Principios Activos: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

–

Principios Activos: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01BC06 - CAPECITABINA
Principios Activos: N/A

Experimental

YERVOY 5 mg/ml concentrate for solution for infusion

SOLUTION FOR INFUSION
UNKNOWN USE

Código ATC: L01FX04 - IPILIMUMAB
Principios Activos: N/A

Experimental

PEMETREXED

POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
INTRAVENOUS USE

–

Principios Activos: N/A

Experimental

Temozolomide SUN 5 mg hard capsules

CAPSULE, HARD
ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA
Principios Activos: N/A

Experimental

Fluorouracil 50 mg/ml Solution for Injection or Infusion

SOLUTION FOR INJECTION/INFUSION
INTRAVENOUS USE

Código ATC: L01BC02 - FLUOROURACILO
Principios Activos: N/A

Experimental

CABOMETYX 20 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Código ATC: L01EX07 - CABOZANTINIB

Principios Activos: N/A

Experimental

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Temozolomide SUN 5 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01AX03 - TEMOZOLOMIDA

Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET

ORAL USE

Principios Activos: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01BC06 - CAPECITABINA

Principios Activos: N/A

Experimental

Sutent 50 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01EX01 - SUNITINIB

Principios Activos: N/A

Experimental

SUNITINIB

CAPSULE, HARD

ORAL USE

Rubraca 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

-	
Principios Activos: N/A	Experimental

Código ATC: L01XK03 - RUCAPARIB	
Principios Activos: N/A	Experimental

ALIMTA 100 mg powder for concentrate for solution for infusion SOLUTION FOR INFUSION INTRAVENOUS USE	
Código ATC: L01BA04 - PEMETREXED	
Principios Activos: N/A	Experimental

Nivolumab/Relatlimab SOLUTION FOR INFUSION UNKNOWN USE	
-	
Principios Activos: N/A	Experimental

Sin resultados

Pan tumor Roll Over Study

State
Recruiting

Type of participants
Not provided

Age Ranges
Older than 64 , Adults (18-64 years)

Gender
Both

Phases
Phase II

Expected Participants
281

Results
No results

Low level of intervention
No

Rare disease
No

Geographic coverage
Undetermined

Areas of the study
safety

Advanced therapy
NO

Information

Identifier
2023-506914-32-00 (CTIS)

Protocol Code
CA209-8TT

Transitioned 2018-004362-34

Therapeutic area
Diseases [C] - Cancer [C04]

Investigated Disease
Pan tumor

Scientific Title
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Rationale

Not provided

Main Objective

The main objective of this study is to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.

Primary Endpoints

Incidence of adverse events (including related AEs, AEs leading to discontinuation, SAEs, select AEs, immune-mediated AEs, and deaths).

Temporary moments of secondary assessment

Not provided

Secondary Objective

To follow participants who have completed therapy and are in or have completed follow-up on a Parent Study investigating nivolumab or nivolumab combination therapy for long-term efficacy (including overall survival [OS])
Safety of cancer therapies used as comparator in Parent Studies

Secondary Endpoints

OS defined as date of randomization, first dose, or as defined in the Parent Study until date of death from any cause or censored on the last known alive date in the rollover study
Incidence of AEs.

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Signed Written Informed Consent
Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
Participant is eligible to receive continued study treatment per the Parent Study, including treatment beyond

progression per investigator assessment in the Parent Study.
Participant is on treatment hold in the Parent Study following longlasting response or are eligible for treatment rechallenge as defined in the Parent Study.

Exclusion criteria

For Participants planning to enter the study on nivolumab treatment: Participant is not eligible for study treatment per the Parent Study eligibility criteria

Participants with any condition which, in the judgment of the Investigator, may pose a significant risk to the participant.

In the case of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, symptoms must have completely resolved and based on investigator assessment, there are no sequelae that would place the participant at a higher risk of receiving investigational treatment.

Participants currently in other interventional trials, including those for coronavirus disease 2019 (COVID-19), may not participate in BMS clinical trials until the protocol-specific washout period is achieved. If a study participant has received an investigational COVID-19 vaccine or other investigational product designed to treat or prevent COVID-19 prior to screening, enrollment must be delayed until the biologic impact of the vaccine or investigational product is stabilized, as determined by the investigator

Participants not receiving clinical benefit as assessed by the Investigator

Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant

History of allergy or hypersensitivity to study drug components

Prisoners or participants who are involuntarily incarcerated (Note: Under certain specific circumstances and only in countries where local regulations permit, a person who has been imprisoned may be included or permitted to continue as a participant. Strict conditions apply and BMS approval is required

Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness

Dementia or serious psychiatric condition that may compromise the informed consent process and increase the risks associated with study participation

Calendar

(Last Update: 24/06/2026)

Authorization 31/01/2020	Start of Trial 07/07/2020	First patient inclusion 07/07/2020	Halted Not aported	Restarted Not aported
End of recruitment Not aported	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) Not aported

Sponsor

Bristol-Myers Squibb Services Unlimited Company Ireland

Plaza 254Blanchardstown Corporate Park 2

Contact Person

GSM-CT

003223527611

mg-gsm-ct@bms.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Sites

Closed (24/05/2024)	CENTRO ONCOLÓGICO MD ANDERSON INTERNATIONAL ESPAÑA Madrid MADRID Oncology Department
not initialized (---/---/----)	Clinica Universidad De Navarra Pamplona NAVARRA MEDICAL IMMUNOLOGY AND IMMUNOTHERAPY
not initialized (---/---/----)	Clinica Universidad De Navarra Madrid MADRID MEDICAL IMMUNOLOGY AND IMMUNOTHERAPY
Closed (18/09/2024)	COMPLEXO HOSPITALARIO UNIVERSITARIO A CORUÑA Coruña, A CORUÑA
Active (05/11/2020)	CONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA Valencia VALENCIA Oncology Department
Closed (15/05/2024)	FUNDACIÓN ONKOLOGIKOA FUNDAZIOA Donostia/San Sebastián GUIPÚZCOA Oncology Department
Closed (10/09/2024)	HOSPITAL CLÍNIC DE BARCELONA Barcelona BARCELONA Oncology Department
Active (05/04/2024)	Hospital Clinic De Barcelona Barcelona BARCELONA Oncology

not initialized (---/---/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Oncology

Closed (15/09/2022)

HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE

Alicante/Alacant

ALICANTE

Active (25/11/2020)

Hospital General Universitario De Valencia

Valencia

VALENCIA

Oncology

Closed (20/09/2024)

HOSPITAL RAMÓN Y CAJAL

Madrid

MADRID

Oncology Department

Active (02/10/2020)

HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL DE BADALONA

Badalona

BARCELONA

not initialized (---/---/----)

Hospital Universitari Vall D Hebron

Barcelona

BARCELONA

Oncology

Active (22/01/2021)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Closed (21/04/2022)

HOSPITAL UNIVERSITARIO DE BURGOS

Burgos

BURGOS

Active (21/09/2020)

HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ

Madrid

MADRID

not initialized (---/---/----)

Hospital Universitario Fundacion Jimenez Diaz

Madrid

MADRID

Oncology

not initialized (---/---/----)

Hospital Universitario Hm Sanchinarro

Madrid

MADRID

Oncology

Closed (19/12/2025)

Hospital Universitario La Paz

Madrid

MADRID

Oncology

Active (25/06/2020)

HOSPITAL UNIVERSITARIO MADRID SANCHINARRO

Madrid

MADRID

not initialized (---/---/----)

Hospital Universitario Marques De Valdecilla

Santander

CANTABRIA

Oncology

Closed (31/07/2025)

HOSPITAL UNIVERSITARIO REGIONAL DE MÁLAGA

Málaga

MÁLAGA

Closed (31/07/2025)

Hospital Universitario Regional De Malaga

Malaga

MÁLAGA

Oncology

Closed (19/07/2024)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO

Sevilla

SEVILLA

Oncología

Closed (10/07/2024)

HOSPITAL UNIVERSITARIO VIRGEN MACARENA

Sevilla

SEVILLA

Active (11/11/2021)

HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE

Valencia

VALENCIA

Active (10/11/2020)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

not initialized (---/---/----)

Hospital Universitario 12 De Octubre

Madrid

MADRID

Oncology

not initialized (---/---/----)

Institut Catala D'oncologia

Badalona

BARCELONA

oncology

Closed (14/05/2025)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Medication

PEMBROLIZUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

-

Active Principles: N/A

Experimental

Mekinist 0.5 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

ATC code: L01EE01 - TRAMETINIB

Active Principles: N/A

Experimental

Sodiofolin 50 mg/ml, solution for injection/infusion

SOLUTION FOR INJECTION/INFUSION
INTRAVENOUS USE

ATC code: V03AF06 - FOLINATO DE SODIO

Active Principles: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Experimental

SUNITINIB

CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

Temozolomide SUN 20 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

SUNITINIB

CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

Sutent 37.5 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

-

Active Principles: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

-

Active Principles: N/A

Experimental

RUCAPARIB

TABLET
ORAL USE

-

Active Principles: N/A

Experimental

Relatlimab

SOLUTION FOR INFUSION
UNKNOWN USE

-

Active Principles: N/A

Experimental

Avastin 25 mg/ml concentrate for solution for infusion.

SOLUTION FOR INFUSION
INTRAVENOUS USE

Mekinist 2 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

ATC code: L01FG01 - BEVACIZUMAB

Active Principles: N/A

Experimental

ATC code: L01EE01 - TRAMETINIB

Active Principles: N/A

Experimental

Temozolomide SUN 250 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Temozolomide SUN 20 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Temozolomide SUN 140 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Sutent 12.5 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

OXALIPLATIN

CONCENTRATE FOR SOLUTION FOR INFUSION
INTRAVENOUS USE

-

Active Principles: N/A

Experimental

PEMETREXED

POWDER FOR CONCENTRATE FOR SOLUTION FOR
INFUSION
INTRAVENOUS USE

-

Active Principles: N/A

Experimental

OPDIVO 10 mg/mL concentrate for solution for infusion.

SOLUTION FOR INFUSION
UNKNOWN USE

ATC code: L01FF01 - NIVOLUMAB

Active Principles: N/A

Experimental

Mekinist 0.5 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

ATC code: L01EE01 - TRAMETINIB

Active Principles: N/A

Experimental

TRAMETINIB

FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD
ORAL USE

-

Active Principles: N/A

Experimental

Temozolomide SUN 100 mg hard capsules

CAPSULE, HARD
ORAL USE

FLUOROURACIL

SOLUTION FOR INJECTION
INTRAVENOUS USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

-

Active Principles: N/A

Experimental

CABOMETYX 40 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01EX07 - CABOZANTINIB

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Sutent 25 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

Rubraca 200 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01XK03 - RUCAPARIB

Active Principles: N/A

Experimental

BEVACIZUMAB

SOLUTION FOR INFUSION

INTRAVENOUS USE

-

Active Principles: N/A

Experimental

OPDIVO 10 mg/mL concentrate for solution for infusion.

SOLUTION FOR INFUSION

UNKNOWN USE

ATC code: L01FF01 - NIVOLUMAB

Active Principles: N/A

Experimental

DARZALEX 20 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

KEYTRUDA 25 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

ATC code: L01FC01 - DARATUMUMAB

Active Principles: N/A

Experimental

ATC code: L01FF02 - PEMBROLIZUMAB

Active Principles: N/A

Experimental

CABOZANTINIB

FILM-COATED TABLET

ORAL USE

-

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Sutent 37.5 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET

ORAL USE

-

Active Principles: N/A

Experimental

Avastin 25 mg/ml concentrate for solution for infusion.

SOLUTION FOR INFUSION

INTRAVENOUS USE

ALIMTA 500 mg powder for concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

ATC code: L01FG01 - BEVACIZUMAB

Active Principles: N/A

Experimental

ATC code: L01BA04 - PEMETREXED

Active Principles: N/A

Experimental

Mekinist 2 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01EE01 - TRAMETINIB

Active Principles: N/A

Experimental

DARZALEX 20 mg/mL concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

ATC code: L01FC01 - DARATUMUMAB

Active Principles: N/A

Experimental

Stivarga 40 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01XE21 - REGORAFENIB

Active Principles: N/A

Experimental

Temozolomide SUN 100 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Temozolomide SUN 180 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Oxaliplatin 5 mg/ml concentrate for solution for infusion

SOLUTION FOR INFUSION

INTRAVENOUS USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

ATC code: L01XA03 - OXALIPLATINO

Active Principles: N/A

Experimental

Sutent 50 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

Sutent 25 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

Rubraca 250 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

ATC code: L01XK03 - RUCAPARIB

Active Principles: N/A

Experimental

Relatlimab

SOLUTION FOR INJECTION
SOLUTION FOR INFUSION

Active Principles: N/A

Experimental

BEVACIZUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

Active Principles: N/A

Experimental

DARATUMUMAB

SOLUTION FOR INFUSION
INTRAVENOUS USE

Active Principles: N/A

Experimental

Stivarga 40 mg film-coated tablets

FILM-COATED TABLET
ORAL USE

Temozolomide SUN 250 mg hard capsules

CAPSULE, HARD
ORAL USE

ATC code: L01XE21 - REGORAFENIB

Active Principles: N/A

Experimental

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD

ORAL USE

-

Active Principles: N/A

Experimental

Temozolomide SUN 180 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

SUNITINIB

CAPSULE, HARD

ORAL USE

-

Active Principles: N/A

Experimental

Sutent 12.5 mg hard capsules

CAPSULE, HARD

OTHER USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

YERVOY 5 mg/ml concentrate for solution for infusion

SOLUTION FOR INFUSION

UNKNOWN USE

TRAMETINIB

FILM-COATED TABLET

ORAL USE

ATC code: L01FX04 - IPILIMUMAB

Active Principles: N/A

Experimental

-

Active Principles: N/A

Experimental

REGORAFENIB

FILM-COATED TABLET

ORAL USE

-

Active Principles: N/A

Experimental

DISODIUM FOLINATE

SOLUTION FOR INJECTION/INFUSION

INTRAVENOUS USE

-

Active Principles: N/A

Experimental

Temozolomide SUN 140 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

TEMOZOLOMIDE

CAPSULE, HARD

ORAL USE

-

Active Principles: N/A

Experimental

Xtandi 40 mg soft capsules

CAPSULE, SOFT

ORAL USE

ATC code: L02BB04 - ENZALUTAMIDA

Active Principles: N/A

Experimental

ENZALUTAMIDE

CAPSULE, SOFT

ORAL USE

-

Active Principles: N/A

Experimental

CABOZANTINIB

FILM-COATED TABLET

ORAL USE

TEMOZOLOMIDE

CAPSULE, HARD

ORAL USE

Active Principles: N/A

Experimental

Active Principles: N/A

Experimental

TEMOZOLOMIDE
CAPSULE, HARD
ORAL USE

Active Principles: N/A

Experimental

Capecitabine Accord 150 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

ATC code: L01BC06 - CAPECITABINA
Active Principles: N/A

Experimental

YERVOY 5 mg/ml concentrate for solution for infusion
SOLUTION FOR INFUSION
UNKNOWN USE

ATC code: L01FX04 - IPILIMUMAB
Active Principles: N/A

Experimental

PEMETREXED
POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
INTRAVENOUS USE

Active Principles: N/A

Experimental

Temozolomide SUN 5 mg hard capsules
CAPSULE, HARD
ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA
Active Principles: N/A

Experimental

Fluorouracil 50 mg/ml Solution for Injection or Infusion
SOLUTION FOR INJECTION/INFUSION
INTRAVENOUS USE

ATC code: L01BC02 - FLUOROURACILO
Active Principles: N/A

Experimental

CABOMETYX 20 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

Capecitabine Accord 150 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

ATC code: L01EX07 - CABOZANTINIB

Active Principles: N/A

Experimental

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Capecitabine Accord 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Temozolomide SUN 5 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01AX03 - TEMOZOLOMIDA

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

CAPECITABINE

FILM-COATED TABLET

ORAL USE

Active Principles: N/A

Experimental

Capecitabine Accord 500 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01BC06 - CAPECITABINA

Active Principles: N/A

Experimental

Sutent 50 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01EX01 - SUNITINIB

Active Principles: N/A

Experimental

SUNITINIB

CAPSULE, HARD

ORAL USE

Rubraca 300 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

-
Active Principles: N/A

Experimental

ATC code: L01XK03 - RUCAPARIB
Active Principles: N/A

Experimental

ALIMTA 100 mg powder for concentrate for
solution for infusion
SOLUTION FOR INFUSION
INTRAVENOUS USE

ATC code: L01BA04 - PEMETREXED
Active Principles: N/A

Experimental

Nivolumab/Relatlimab
SOLUTION FOR INFUSION
UNKNOWN USE

-
Active Principles: N/A

Experimental

No results